Population dynamics of cross-protection against β-lactam antibiotics in droplet microreactors

Front Microbiol. 2023 Dec 21:14:1294790. doi: 10.3389/fmicb.2023.1294790. eCollection 2023.

Abstract

Introduction: Bacterial strains that are resistant to antibiotics may protect not only themselves, but also sensitive bacteria nearby if resistance involves antibiotic degradation. Such cross-protection poses a challenge to effective antibiotic therapy by enhancing the long-term survival of bacterial infections, however, the current understanding is limited.

Methods: In this study, we utilize an automated nanoliter droplet analyzer to study the interactions between Escherichia coli strains expressing a β-lactamase (resistant) and those not expressing it (sensitive) when exposed to the β-lactam antibiotic cefotaxime (CTX), with the aim to define criteria contributing to cross-protection.

Results: We observed a cross-protection window of CTX concentrations for the sensitive strain, extending up to approximately 100 times its minimal inhibitory concentration (MIC). Through both microscopy and enzyme activity analyses, we demonstrate that bacterial filaments, triggered by antibiotic stress, contribute to cross-protection.

Discussion: The antibiotic concentration window for cross-protection depends on the difference in β-lactamase activity between co-cultured strains: larger differences shift the 'cross-protection window' toward higher CTX concentrations. Our findings highlight the dependence of opportunities for cross-protection on the relative resistance levels of the strains involved and suggest a possible specific role for filamentation.

Keywords: antibiotic resistance; bacterial cross-protection; cell filamentation; droplet-based microreactors; β-lactam antibiotics.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was funded by the Deutsche Forschungsgemeinschaft (DFG) in projects Nr.BA4986/8–1, and GRK 2767 and Human Frontiers in Science Program grant RGP0010/2015. Furthermore, LB acknowledges the financial support of the project ImmunoChip which has received funding from the European Research Council (ERC) under the European Union’s Horizon Europe research and innovation program grant agreement No. 101045415.